Attralus

📍 San Francisco, United States👥 30 employees💰 Last funded Aug 2020
Biotechnology Research🌐 attralus.com
Website LinkedIn
Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Our proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Attralus?
Attralus has 1 investors on record on gritt.io.
When did Attralus last raise funding?
The most recent investment in Attralus recorded on gritt.io was in August 2020.
What industry is Attralus in?
Attralus operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Attralus based?
Attralus is headquartered in San Francisco, United States.